Where can I buy Zogenix (zgnx)?
Shares of ZGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Zogenix's stock price today?
What happened to the Zogenix stock price?
The Zogenix stock price fell by -0.15% on the last day (Friday, 18th Feb 2022) from $26.16 to $26.12. and has now fallen 4 days in a row. During the day the stock fluctuated 0.56% from a day low at $26.10 to a day high of $26.25. The price has been going up and down for this period, and there has been a 0.11% gain for the last 2 weeks.
Does Zogenix have an upside of 110%?
According to analysts' consensus price target of $32.95, Zogenix has a forecasted upside of 110.0% from its current price of $15.69. Zogenix has only been the subject of 3 research reports in the past 90 days. Zogenix has received 487 “outperform” votes. (Add your “outperform” vote.) Zogenix has received 193 “underperform” votes.
Is zgnx stock a buy or sell?
Losses were -$227.41 million, 8.61% more than in 2020. According to 15 analysts, the average rating for ZGNX stock is "Buy." The 12-month stock price forecast is 37.3, which is an increase of 39.81% from the latest price.
Is zogenix publicly traded?
As a result of the merger, Zogenix has become a wholly-owned subsidiary of UCB and the common stock of Zogenix will be delisted from the NASDAQ Global Market.
Is zogenix a buy?
Zogenix has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 6 hold ratings, and no sell ratings.
When did zogenix go public?
March 03, 2020EMERYVILLE, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc.
Is zogenix a good company?
Excellent Company Great company culture and management. Great benefits and a great product that is successful. Not much room for advancement unless you are in management.
Is zogenix a buy Zacks?
The VGM Score are a complementary set of indicators to use alongside the Zacks Rank....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy24.75%2Buy18.15%3Hold9.70%4Sell5.35%2 more rows
Who bought zogenix?
UCBUCB has concluded the previously announced acquisition of international biopharmaceutical firm Zogenix in a deal valued at up to roughly $1.9bn (€1.7bn). In January, UCB signed a definitive agreement for acquiring all outstanding shares of Zogenix.
What is dravet?
Definition. Dravet syndrome, previously called severe myoclonic epilepsy of infancy (SMEI), is an epilepsy syndrome that begins in infancy or early childhood and can include a spectrum of symptoms ranging from mild to severe.
Is ZGNX stock a buy right now?
9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zogenix in the last year. There are currently 7 hold rat...
Will Zogenix's stock price go up in 2022?
9 analysts have issued 12 month target prices for Zogenix's shares. Their forecasts range from $17.67 to $62.00. On average, they predict Zogenix's...
How were Zogenix's earnings last quarter?
Zogenix, Inc. (NASDAQ:ZGNX) issued its quarterly earnings data on Thursday, November, 4th. The company reported ($1.04) EPS for the quarter, missin...
Who are Zogenix's key executives?
Zogenix's management team includes the following people: Stephen James Farr , President, Chief Executive Officer & Director Ashish M. Sagrolikar...
What is Stephen Farr, Ph.D.'s approval rating as Zogenix's CEO?
7 employees have rated Zogenix CEO Stephen Farr, Ph.D. on Glassdoor.com . Stephen Farr, Ph.D. has an approval rating of 85% among Zogenix's employ...
Who are some of Zogenix's key competitors?
Some companies that are related to Zogenix include Johnson & Johnson (JNJ) , Pfizer (PFE) , Eli Lilly and (LLY) , AbbVie (ABBV) , Merck & Co.,...
What other stocks do shareholders of Zogenix own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Zogenix investors own include GW Pharmaceuticals (GWPH) ,...
What is Zogenix's stock symbol?
Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."
Who are Zogenix's major shareholders?
Zogenix's stock is owned by many different retail and institutional investors. Top institutional shareholders include Walleye Trading LLC (0.00%),...
When will Zogenix release its results?
Why is Zogenix under pressure?
Zogenix to Release Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 5. EMERYVILLE, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial...
Zogenix (NASDAQ:ZGNX) Price Target and Consensus Rating
Shares of Zogenix have been under pressure lately due to safety concerns surrounding its unique anti-epileptic drug, Fintepla. Despite receiving FDA approval for a rare and serious epileptic condition, ...
Analyst Ratings By Month
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).
Average Share Price and Price Target by Month
The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Zogenix (NASDAQ:ZGNX) Analyst Ratings Frequently Asked Questions
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target.
Signals & Forecast
According to the issued ratings of 9 analysts in the last year, the consensus rating for Zogenix stock is Hold based on the current 6 hold ratings and 3 buy ratings for ZGNX. The average twelve-month price target for Zogenix is $32.10 with a high price target of $62.00 and a low price target of $17.67. Learn more on ZGNX's analyst rating history
Support, Risk & Stop-loss
A sell signal was issued from a pivot top point on Tuesday, February 01, 2022, and so far it has fallen -0.83%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).
Is Zogenix stock A Buy?
Zogenix finds support from accumulated volume at $25.98 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Insiders are very positive buying more shares than they are selling in Zogenix
Several of the signals/indicators are negative, and we believe that this will affect on the development for the next days and maybe possible weeks. However, over time, we think that today's level holds a possible buying opportunity and that the price will be higher during or at the end of this 3-month period.
About Zogenix
In the last 100 trades there were 856.08 thousand shares bought and 168.84 thousand shares sold. The last trade was done 37 days ago by Mast Erle T who sold 4.38 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Golden Star Signal
Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. The companys lead product candidate is the ZX008, a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
What happened
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
So what
Shares of the small-cap drugmaker Zogenix (NASDAQ: ZGNX) rose by as much as 67% in pre-market trading Wednesday morning. The company's shares are surging higher today in response to a buyout agreement with the Belgian pharmaceutical company UCB.
Now what
Zogenix's stock has been losing ground steadily over the prior 12 months despite Fintepla's stellar commercial potential. Keeping with this theme, Wall Street expects the drug's 2024 sales to come in at approximately $467 million. That's a sizable sum for a company that had a market cap under $900 million as of Tuesday's closing bell.
The Motley Fool
Is Zogenix stock still worth buying for the contingent value right? Probably not. Regulatory reviews are unpredictable. And this regulatory risk simply isn't worth a possible 6% to 7% gain.
